Core Insights - Apogee Therapeutics, Inc. is set to report interim results from its Phase 1b trial of APG777 for mild-to-moderate asthma on January 6, 2026, followed by a conference call and webcast at 8:00 a.m. ET [1] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized, novel biologics for the inflammatory and immunology (I&I) markets, including treatments for atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications [3] - The company's lead program, APG777, targets the treatment of AD, which is identified as the largest and least penetrated market within the I&I sector [3] - Apogee's antibody programs aim to address the limitations of existing therapies by utilizing established mechanisms of action and advanced antibody engineering to enhance properties such as half-life [3] - The company has four validated targets in its portfolio and is pursuing best-in-class efficacy and dosing through both monotherapies and combinations of its novel antibodies [3]

Company Overview - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology (I&I) markets, targeting conditions such as atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD) [3] - The company aims to overcome limitations of existing therapies by utilizing advanced antibody engineering to optimize properties like half-life, with a focus on achieving best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies [3] Upcoming Events - Apogee Therapeutics will report Part A 16-week data from the Phase 2 APEX trial of its lead program APG777 on July 7, 2025, followed by a conference call and webcast at 8:00 a.m. ET to discuss the results [1][2] Product Pipeline - APG777 is the most advanced program of Apogee, initially developed for the treatment of atopic dermatitis, which is identified as the largest and one of the least penetrated I&I markets [3] - The company has four validated targets in its portfolio, indicating a broad pipeline and depth of expertise aimed at delivering value and meaningful benefits to patients underserved by current standard care [3]